GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: ABBV/GLPG-3221 | compound 19 [PMID: 31749908]
                                 
                                                         
                            Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: ABBV-3221(GLPG-3221) is a novel cystic fibrosis transmembrane conductance regulator (CFTR) corrector that is being developed in a collaboration between AbbVie and Galapagos for the treatment of cystic fibrosis [2]. It was designed to provide improved clinical efficacy when used in a triple combination with a CFTR potentiator and a second, but mechanistically distinct, corrector molecule. ABBV-3221 enhances channel activity by increasing pore opening whilst the channel's two nucleotide-binding domains are dimerized [1].
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| References | 
| 
                                                                         1. Levring J, Terry DS, Kilic Z, Fitzgerald G, Blanchard SC, Chen J. (2023)
                                         CFTR function, pathology and pharmacology at single-molecule resolution. Nature, 616 (7957): 606-614. [PMID:36949202]  | 
                                                                
| 
                                                                         2. Scanio MJC, Searle XB, Liu B, Koenig JR, Altenbach R, Gfesser GA, Bogdan A, Greszler S, Zhao G, Singh A et al.. (2019)
                                         Discovery of ABBV/GLPG-3221, a Potent Corrector of CFTR for the Treatment of Cystic Fibrosis. ACS Med Chem Lett, 10 (11): 1543-1548. [PMID:31749908]  |